207 related articles for article (PubMed ID: 19129046)
1. On Two-stage Seamless Adaptive Design in Clinical Trials.
Chow SC; Tu YH
J Formos Med Assoc; 2008 Dec; 107(12 Suppl):52-60. PubMed ID: 19129046
[TBL] [Abstract][Full Text] [Related]
2. Statistical analysis for two-stage seamless design with different study endpoints.
Chow SC; Lu Q; Tse SK
J Biopharm Stat; 2007; 17(6):1163-76. PubMed ID: 18027223
[TBL] [Abstract][Full Text] [Related]
3. Analysis of time-to-event data under a two-stage survival adaptive design in clinical trials.
Lu Q; Tse SK; Chow SC
J Biopharm Stat; 2010 Jul; 20(4):705-19. PubMed ID: 20496201
[TBL] [Abstract][Full Text] [Related]
4. Analysis of time-to-event data with nonuniform patient entry and loss to follow-up under a two-stage seamless adaptive design with weibull distribution.
Lu Q; Tse SK; Chow SC; Lin M
J Biopharm Stat; 2012; 22(4):773-84. PubMed ID: 22651114
[TBL] [Abstract][Full Text] [Related]
5. Analysis of innovative two-stage seamless adaptive design with different endpoints and population shift.
Mai W; Chow SC
J Biopharm Stat; 2024 Mar; ():1-14. PubMed ID: 38515269
[TBL] [Abstract][Full Text] [Related]
6. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
Schmidt R; Burkhardt B; Faldum A
Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
[TBL] [Abstract][Full Text] [Related]
7. Sample size estimation based on event data for a two-stage survival adaptive trial with different durations.
Lu Q; Chow SC; Tse SK; Chi Y; Yang LY
J Biopharm Stat; 2009; 19(2):311-23. PubMed ID: 19212882
[TBL] [Abstract][Full Text] [Related]
8. Benefits, challenges and obstacles of adaptive clinical trial designs.
Chow SC; Corey R
Orphanet J Rare Dis; 2011 Nov; 6():79. PubMed ID: 22129361
[TBL] [Abstract][Full Text] [Related]
9. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
Wang SJ; Hung HM; O'Neill R
J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
[TBL] [Abstract][Full Text] [Related]
10. A free gift: an adaptive strategy in a single-arm trial using an exact test through the binomial distribution.
Wang J
J Biopharm Stat; 2012; 22(6):1127-36. PubMed ID: 23075012
[TBL] [Abstract][Full Text] [Related]
11. Utility of adaptive strategy and adaptive design for biomarker-facilitated patient selection in pharmacogenomic or pharmacogenetic clinical development program.
Wang SJ
J Formos Med Assoc; 2008 Dec; 107(12 Suppl):19-27. PubMed ID: 19129042
[TBL] [Abstract][Full Text] [Related]
12. A case study of an adaptive design for a clinical trial with 2 doses and 2 endpoints in a rare disease area.
Quan H; Xu Y; Chen Y; Gao L; Chen X
Pharm Stat; 2018 Nov; 17(6):797-810. PubMed ID: 30221446
[TBL] [Abstract][Full Text] [Related]
13. Adaptive design methods in clinical trials - a review.
Chow SC; Chang M
Orphanet J Rare Dis; 2008 May; 3():11. PubMed ID: 18454853
[TBL] [Abstract][Full Text] [Related]
14. Adaptive methods: telling "the rest of the story".
Emerson SS; Fleming TR
J Biopharm Stat; 2010 Nov; 20(6):1150-65. PubMed ID: 21058111
[TBL] [Abstract][Full Text] [Related]
15. On sample size determination in multi-armed confirmatory adaptive designs.
Wassmer G
J Biopharm Stat; 2011 Jul; 21(4):802-17. PubMed ID: 21516570
[TBL] [Abstract][Full Text] [Related]
16. Some Issues of Sample Size Calculation for Time-to-Event Endpoints Using the Freedman and Schoenfeld Formulas.
Abel UR; Jensen K; Karapanagiotou-Schenkel I; Kieser M
J Biopharm Stat; 2015; 25(6):1285-311. PubMed ID: 25629760
[TBL] [Abstract][Full Text] [Related]
17. Inference for clinical trials with some protocol amendments.
Chow SC; Shao J
J Biopharm Stat; 2005; 15(4):659-66. PubMed ID: 16022170
[TBL] [Abstract][Full Text] [Related]
18. An adaptive two-stage dose-response design method for establishing proof of concept.
Franchetti Y; Anderson SJ; Sampson AR
J Biopharm Stat; 2013; 23(5):1124-54. PubMed ID: 23957520
[TBL] [Abstract][Full Text] [Related]
19. Adaptive clinical trial designs with blinded selection of binary composite endpoints and sample size reassessment.
Roig MB; Melis GG; Posch M; Koenig F
Biostatistics; 2023 Dec; 25(1):237-252. PubMed ID: 36150142
[TBL] [Abstract][Full Text] [Related]
20. An Adaptive Staggered Dose Design for a Normal Endpoint.
Wu J; Menon S; Chang M
J Biopharm Stat; 2015; 25(4):731-56. PubMed ID: 24904986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
